MedPath

Nicorandil

Generic Name
Nicorandil
Drug Type
Small Molecule
Chemical Formula
C8H9N3O4
CAS Number
65141-46-0
Unique Ingredient Identifier
260456HAM0
Background

Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used for patients with angina who remain symptomatic despite optimal treatment with other antianginal drugs . Nicorandil is a dual-action potassium channel opener that relaxes vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and increased intracellular concentration of cyclic GMP. It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload .

Indication

Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.

Associated Conditions
Angina Pectoris

Oral Nicorandil in ST Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention

Conditions
Nicorandil
Interventions
First Posted Date
2020-11-17
Last Posted Date
2021-01-05
Lead Sponsor
Ahmed Abdel Nasser Abdel Rady
Target Recruit Count
300
Registration Number
NCT04632121

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase 1
Recruiting
Conditions
Non-Small Cell Lung Cancer
Advanced Solid Tumors
Colorectal Cancer
Interventions
First Posted Date
2020-06-29
Last Posted Date
2025-05-13
Lead Sponsor
Genentech, Inc.
Target Recruit Count
498
Registration Number
NCT04449874
Locations
🇮🇱

Sheba Medical Center - PPDS, Ramat Gan, Israel

🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

🇺🇸

UCSD Moores Cancer Center, La Jolla, California, United States

and more 71 locations

Different Anti-Spastic Therapy Strategies After CABG Using Radial Artery Grafts

Phase 4
Completed
Conditions
Antispastic Therapy
Coronary Artery Bypass Graft
Radial Artery Grafts
Pilot Study
Interventions
First Posted Date
2020-03-17
Last Posted Date
2024-12-12
Lead Sponsor
Ruijin Hospital
Target Recruit Count
150
Registration Number
NCT04310995
Locations
🇨🇳

Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China

RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

Phase 1
Completed
Conditions
Solid Tumor, Unspecified, Adult
Interventions
First Posted Date
2020-02-05
Last Posted Date
2023-01-31
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
56
Registration Number
NCT04252339
Locations
🇺🇸

Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 3 locations

Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging

Phase 2
Active, not recruiting
Conditions
Dementia
Mild Cognitive Impairment
Interventions
Drug: Placebo
First Posted Date
2019-10-09
Last Posted Date
2024-12-27
Lead Sponsor
Gregory Jicha, MD, PhD
Target Recruit Count
64
Registration Number
NCT04120766
Locations
🇺🇸

University of Kentucky, Lexington, Kentucky, United States

Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development

Not Applicable
Completed
Conditions
Insulin Resistance
Interventions
Drug: Placebo
First Posted Date
2018-12-14
Last Posted Date
2023-07-06
Lead Sponsor
University of Copenhagen
Target Recruit Count
16
Registration Number
NCT03775902
Locations
🇩🇰

University of Copenhagen, Copenhagen, Danmark, Denmark

China-Administration of Nicorandil Group(CHANGE)

Phase 4
Completed
Conditions
Percutaneous Coronary Intervention
Myocardial Infarction
Nicorandil
Interventions
Other: Placebo
First Posted Date
2018-02-26
Last Posted Date
2021-11-24
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
238
Registration Number
NCT03445728
Locations
🇨🇳

CHINA, Beijing, China

Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI

Phase 4
Conditions
ST Segment Elevation Myocardial Infarction
Interventions
First Posted Date
2017-08-17
Last Posted Date
2017-08-17
Lead Sponsor
RenJi Hospital
Target Recruit Count
600
Registration Number
NCT03252665
Locations
🇨🇳

Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University, ShangHai, China

Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Participants

Phase 4
Terminated
Conditions
Non-obstructive Coronary Artery Disease
Interventions
First Posted Date
2017-01-05
Last Posted Date
2020-07-07
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
8
Registration Number
NCT03010423
Locations
🇨🇳

Peking union medical college hospital, Beijing, China

Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients

Phase 2
Conditions
Radiation Pneumonitis
Interventions
First Posted Date
2016-06-22
Last Posted Date
2016-06-23
Lead Sponsor
Taipei Medical University WanFang Hospital
Target Recruit Count
50
Registration Number
NCT02809456
© Copyright 2025. All Rights Reserved by MedPath